The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir

被引:178
|
作者
Kempf, DJ
Rode, RA
Xu, Y
Sun, E
Heath-Chiozzi, ME
Valdes, J
Japour, AJ
Danner, S
Boucher, C
Molla, A
Leonard, JM
机构
[1] Abbott Labs, Antiviral Venture, Div Pharmaceut Prod, Abbott Pk, IL 60064 USA
[2] Abbott Labs, Dept Biostat, Abbott Pk, IL 60064 USA
[3] Abbott Labs, Dept Infect Dis Res, Abbott Pk, IL 60064 USA
[4] Univ Amsterdam, Acad Med Ctr, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands
[5] Univ Utrecht, Univ Hosp, Eijkman Winkler Inst Med & Clin MIcrobiol, Utrecht, Netherlands
关键词
viral load; durability of response; protease inhibitor; resistance;
D O I
10.1097/00002030-199805000-00001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To determine markers that are associated with the durability of virologic response to therapy with HIV protease inhibitors in HIV-infected individuals. Design: This study encompassed two retrospective analyses of the duration of virologic response to protease inhibitor therapy. The first analysis included 29 patients receiving either monotherapy or combination therapy with the protease inhibitor ritonavir whose plasma HIV RNA levels rebounded from the point of greatest decline with mutations associated with resistance to ritonavir. The second analysis included a cohort of 102 patients who initially responded to randomized treatment with either monotherapy with ritonavir or combination therapy with ritonavir and zidovudine. Methods: Durability of response was defined as the time from the initiation of therapy to the point at which plasma HIV RNA displayed a sustained increase of at least 0.6 log(10) copies/ml from the nadir value. In the first analysis, durability of response was analyzed with respect to baseline HIV RNA, HIV RNA at the nadir, and the drop in HIV RNA from baseline to the nadir. In the second analysis, time to rebound was examined using Kaplan-Meier analysis, stratifying by either baseline HIV RNA or HIV RNA at the nadir. Results: In both analyses, the durability of response was not highly associated with either baseline RNA or the magnitude of RNA decline from baseline. Instead, a strong relationship was observed between the durability of response and the nadir plasma HIV-1 RNA value (P < 0.01). The nadir in viral load was generally reached after 12 weeks of randomized therapy. Conclusions: Viral RNA determinations at intermediate timepoints may be prognostic of impending virologic failure of protease inhibitor therapy. Therapeutic strategies that allow intensification of initial antiretroviral regimens in the subset of patients with incomplete virological response before the emergence of high level resistance should be investigated. (C) 1998 Rapid Science Ltd.
引用
收藏
页码:F9 / F14
页数:6
相关论文
共 50 条
  • [21] Feasibility of pooling sera for HIV-1 viral RNA to diagnose acute primary HIV-1 infection and estimate HIV incidence
    Quinn, TC
    Brookmeyer, R
    Kline, R
    Shepherd, M
    Paranjape, R
    Mehendale, S
    Gadkari, DA
    Bollinger, R
    AIDS, 2000, 14 (17) : 2751 - 2757
  • [22] HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat
    Fun, Axel
    van Maarseveen, Noortje M.
    Pokorna, Jana
    Maas, Renee E. M.
    Schipper, Pauline J.
    Konvalinka, Jan
    Nijhuis, Monique
    RETROVIROLOGY, 2011, 8
  • [23] HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat
    Axel Fun
    Noortje M van Maarseveen
    Jana Pokorná
    Renée EM Maas
    Pauline J Schipper
    Jan Konvalinka
    Monique Nijhuis
    Retrovirology, 8
  • [24] HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor
    Lisziewicz, J
    Jessen, H
    Finzi, D
    Siliciano, RF
    Lori, F
    LANCET, 1998, 352 (9123): : 199 - 200
  • [25] DETECTION OF HIV-1 RNA IN HEPARINIZED PLASMA OF HIV-1 SEROPOSITIVE INDIVIDUALS
    IMAI, H
    YAMADA, O
    MORITA, S
    SUEHIRO, S
    KURIMURA, T
    JOURNAL OF VIROLOGICAL METHODS, 1992, 36 (02) : 181 - 184
  • [26] Short Communication: Circulating Plasma HIV-1 Viral Protein R in Dual HIV-1/Tuberculosis Infection
    Toossi, Zahra
    Liu, Shigou
    Wu, Mianda
    Mayanja-Kizza, Harriet
    Hirsch, Christina S.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 (07) : 644 - 647
  • [27] The HIV-1 protease inhibitor saquinavir is a radiosensitizer
    Himmelsbach, J
    McBride, WH
    Pajonk, F
    STRAHLENTHERAPIE UND ONKOLOGIE, 2002, 178 : 37 - 37
  • [28] Optimization of a macromolecular inhibitor of HIV-1 protease
    Dauber, DS
    McPhee, F
    Ünal, A
    Craik, CS
    ASPARTIC PROTEINASES: RETROVIRAL AND CELLULAR ENZYMES, 1998, 436 : 65 - 70
  • [29] Suppression of HIV-1 plasma viral load below detection preserves IL-17 producing T cells in HIV-1 infection
    Ndhlovu, Lishomwa C.
    Chapman, Joan M.
    Jha, Aashish R.
    Snyder-Cappione, Jennifer E.
    Pagan, Moraima
    Leal, Fabio E.
    Boland, Brigid S.
    Norris, Philip J.
    Rosenberg, Michael G.
    Nixon, Douglas F.
    AIDS, 2008, 22 (08) : 990 - 992
  • [30] The binding energy of HIV-1 protease inhibitor
    Ka, J
    Park, SH
    Kim, H
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 1996, 17 (01) : 19 - 24